Myeloproliferative neoplasms (MPNs) are a group of hematopoietic stem cell diseases characterized by the excessive production of one or more myeloid lineage with largely intact cellular differentiation. Recent advances in the field, such as the detection of new driver mutations and a better understanding of the molecular pathogenesis of MPNs, have revolutionized the diagnosis, classification and treatment of these hematological malignancies.
The First Texas MPN Workshop brought together medical experts in the field of MPNs to discuss the latest research and therapy options in development for MPNs. In this podcast, Ruben Mesa, MD, FACP, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, Claire Harrison, MD, FRCP, FRCPath, Guy’s and St Thomas’ NHS Foundation Trust, London, UK and Naveen Pemmaraju, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discuss the evolving management of MPNs, including learnings following COVID-19, mutations and molecular definitions of disease, interferon-based therapies, clinical trial updates and takeaways from the 2020 Texas MPN Workshop.
The post The MPN Sessions: pathobiology, therapeutic strategies & clinical trials appeared first on VJHemOnc.
